Inflammaging (chronic age-related systemic inflammation) contributes to virtually every major chronic disease of aging: cardiovascular disease, type 2 diabetes, neurodegeneration, cancer, sarcopenia, and osteoporosis. Senescent cells are one of the primary sources of inflammaging via persistent SASP secretion. Reducing senescent cell burden measurably reduces systemic inflammatory markers.

How quickly do inflammatory markers fall after senolytics?

In clinical trials, SASP-related markers (IL-6, MMP-3) begin declining within the first week post-treatment. The reduction continues over 2–4 weeks as dead senescent cells are cleared by phagocytes. hsCRP typically decreases within 2–4 weeks.

Can senolytics normalize CRP to below 1 mg/L?

In individuals with CRP elevated primarily from senescent cell SASP (rather than active infection, autoimmune disease, or other causes), senolytics can be sufficient to bring CRP to optimal range. Results depend on baseline senescent cell burden and the comprehensiveness of the senolytic protocol.